Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 82

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 2
Chunk 82
---
)                 (LOSS)/PROFIT FROM OPERATIONS  (611,293)  259,168   (1,229,711)  180,140                  FINANCE COSTS  (4,879)  (4,480)  (9,788)  (9,141)                 PROFIT/(LOSS) BEFORE TAX  (616,172)  254,688   (1,239,499)  170,999                  Tax expense  -   (55,584)  -   (75,652)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(616,172) $199,104  $(1,239,499) $95,347                  Other comprehensive income                Foreign currency translation gain  367,078   2,463   439,237   (207,445)                 COMPREHENSIVE (LOSS)/PROFIT $(249,094) $201,567  $(800,262) $(112,098)

 36Table of Contents

Segmented Information

  MRNA Scientific and Chemrex Corporation   Provision for genomic screening services  Trading of industrial chemicals  Provision for genomic screening services  Trading of industrial chemicals   Three months ended June 30, 2025  Three months ended June 30, 2024              REVENUE $3,466  $2,256,787  $5,496  $1,969,068                  COST OF REVENUE  (2,725)  (1,889,506)  (2,353)  (1,683,491)                 GROSS PROFIT  741   367,281   3,143   285,577                  OTHER INCOME                Dividend income   -   8,626   -   11,881 Interest income  25,092   4,676   37,154   12,585 Fair value gain on investments in equity securities  -   23,742   -   88,532 Gain on disposal of investments in equity securities